| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.00 | 0.02 (+0.50%) | 3.76 - 11.88 | 2.1 million (Below Avg) |
Market data as of 4:00PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 4.09 |
|---|---|
| Previous Close | 3.98 |
| Day's Range | 3.92 - 4.14 |
| Market Cap | 276.5M |
| Avg Volume (10 Day) | 2.9M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.09 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Synta to Present at the Jefferies 2013 Global Healthcare Conference
Business Wire - Tuesday 06/04/2013 8:00 AM ET
Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer
Business Wire - Monday 06/03/2013 7:34 AM ET
Synta to Host Investor Meeting and Webcast at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Friday 05/31/2013 4:03 PM ET
| SNTA | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.42 | |
| LT Debt/Equity | 0.36 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Curis Inc | 3.44 | +0.58% |
| Novavax Inc | 1.92 | +1.05% |
| Coronado Biosciences Inc | 9.10 | -2.05% |
| Sunesis Pharmaceuticals Inc | 5.02 | +0.20% |
| OvaScience Inc | 13.93 | 0.00% |
Data is delayed by at least 15 min.